LYNCH & ASSOCIATES/IN - Q3 2018 holdings

$296 Million is the total value of LYNCH & ASSOCIATES/IN's 99 reported holdings in Q3 2018. The portfolio turnover from Q2 2018 to Q3 2018 was 5.6% .

 Value Shares↓ Weighting
ABT  ABBOTT LABORATORIES$4,068,000
+20.3%
55,4490.0%1.37%
+12.1%
GABC  GERMAN AMERICAN BANCORP$992,000
-1.6%
28,1170.0%0.34%
-8.2%
CSX  CSX CORP$922,000
+16.1%
12,4550.0%0.31%
+8.0%
XLK  TECHNOLOGY SELECT SECTOR SPDRetf$864,000
+8.4%
11,4750.0%0.29%
+1.0%
BMY  BRISTOL-MYERS SQUIBB CO$840,000
+12.1%
13,5330.0%0.28%
+4.8%
AMZN  AMAZON COM$733,000
+17.8%
3660.0%0.25%
+9.8%
BRKB  BERKSHIRE HATHAWAY INC CL B$563,000
+14.7%
2,6310.0%0.19%
+6.7%
RF  REGIONS FINANCIAL CORP$435,000
+3.1%
23,7140.0%0.15%
-3.9%
XLV  HEALTH CARE SELECT SECTOR SPDRetf$390,000
+14.0%
4,1000.0%0.13%
+6.5%
XLY  CONSUMER DISCRETIONARY SELECTetf$328,000
+7.2%
2,8000.0%0.11%0.0%
NKE  NIKE INC$263,000
+6.0%
3,1080.0%0.09%
-1.1%
CINF  CINCINNATI FINL CORP$257,000
+14.7%
3,3450.0%0.09%
+7.4%
NI  NISOURCE INC$251,000
-5.3%
10,0800.0%0.08%
-11.5%
XLP  CONSUMER STAPLES SELECT SECTORetf$232,000
+4.5%
4,3000.0%0.08%
-2.5%
FCF  FIRST COMMONWEALTH FINANCIAL$211,000
+3.9%
13,1000.0%0.07%
-4.1%
OTTW  OTTAWA BANCORP INC$139,0000.0%10,0000.0%0.05%
-6.0%
CGEN  COMPUGEN LTD$39,000
+18.2%
10,0000.0%0.01%
+8.3%
NAVB  NAVIDEA BIOPHARMACEUTICALS INC$4,0000.0%18,0000.0%0.00%0.0%
BRBI  BLUE RIVER BANCSHARES INC$038,0720.0%0.00%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2018-10-05
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
MICROSOFT CORP43Q4 202310.1%
UNITED PARCEL SERVICE INC43Q4 20239.9%
JOHNSON & JOHNSON43Q4 20235.0%
EXXON MOBIL CORP43Q4 20235.5%
ISHARES CORE S&P MIDCAP 400 IN43Q4 20234.0%
ISHARES CORE S&P 500 INDEX43Q4 20234.1%
PROCTER & GAMBLE CO43Q4 20234.2%
INTEL CORP43Q4 20234.2%
PFIZER INC43Q4 20233.2%
WAL-MART STORES INC43Q4 20233.2%

View LYNCH & ASSOCIATES/IN's complete holdings history.

Latest filings
TypeFiled
13F-HR2024-04-09
13F-HR2024-01-08
13F-HR/A2023-10-24
13F-HR/A2023-10-24
13F-HR/A2023-10-24
13F-HR/A2023-10-24
13F-HR2023-10-24
13F-HR2023-07-13
13F-HR2023-04-04
13F-HR2023-01-05

View LYNCH & ASSOCIATES/IN's complete filings history.

Compare quarters

Issues

The following issues were detected while analyzing the report:

  • The reported total value is incorrect (296297000.0 != 296294000.0)

Export LYNCH & ASSOCIATES/IN's holdings